Kennedy Boulevard Dialysis is a medicare approved dialysis facility center in Tampa, Florida and it has 20 dialysis stations. It is located in Hillsborough county at 2205 W Kennedy Blvd, Tampa, FL, 33606. You can reach out to the office of Kennedy Boulevard Dialysis at (813) 254-3638. This dialysis clinic is managed and/or owned by Davita. Kennedy Boulevard Dialysis has the following ownership type - Profit. It was first certified by medicare in February, 2016. The medicare id for this facility is 682596 and it accepts patients under medicare ESRD program.
| Name | Kennedy Boulevard Dialysis |
|---|---|
| Location | 2205 W Kennedy Blvd, Tampa, Florida |
| No. of Dialysis Stations | 20 |
| Medicare ID | 682596 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 2205 W Kennedy Blvd, Tampa, Florida, 33606 | |
| (813) 254-3638 | |
| Not Available |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
| NPI Number | 1871971556 |
| Organization Name | Kennedy Boulevard Dialysis |
| Doing Business As | Brache Dialysis Llc |
| Address | 2205 W Kennedy Blvd Tampa, Florida, 33606 |
| Phone Number | (813) 254-3638 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
| Dialysis patients with Hemoglobin data | 20 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 25 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 45 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 336 |
| Percentage of adult patients getting regular hemodialysis at the center | 89 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Kennedy Boulevard Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 45 |
| Hypercalcemia patient months | 336 |
| Patients with Serumphosphor | 48 |
| Patients with Serumphosphor less than 3.5 mg/dL | 11 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 63 |
| Patient months included in arterial venous fistula and catheter summaries | 254 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 59 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 26 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 16 |
The rate of readmission show you whether patients who were being treated regularly at Kennedy Boulevard Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 41.6 |
| Readmission Rate: Lower Confidence Limit | 8.9 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Kennedy Boulevard Dialysis get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 2.77 (As Expected) |
| SIR: Upper Confidence Limit | 6.68 |
| SIR: Lower Confidence Limit | .88 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Kennedy Boulevard Dialysis's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 13 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
The rate of mortality show you whether patients who were being treated regularly at Kennedy Boulevard Dialysis lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 25 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago
Central Tampa Dialysis Location: 4204 N Macdill Ave South Bldg, Tampa, Florida, 33607 Phone: (813) 871-3202 |
News Archive
Sermo, the world's largest online community for physicians, today announced a Sermo Event Report titled "Is there any Threat to Anti-TNFs from Newer Biologic DMARDs?" In the past year, the FDA has approved four new biologic DMARDs – Actemra (Genentech), Orencia (Bristol-Myers Squibb), Simponi (Centocor Ortho Biotech), and Cimzia (UCB). According to the report, Orencia leads the pack among physicians as the next line of treatment for patients who fail two or more TNF antagonists.
Cutting-edge 3D scanners have been put to the test by researchers from the University of Southampton and partners Exceed Worldwide to help increase the quality and quantity of prosthetics services around the world.
Research has documented the widespread availability of graphic images of self-harm, such as cuttings, on the photo-sharing platform Instagram.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 6 days ago